Antiretroviral therapy in resource-limited settings 1996 to 2006: Patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America

Tropical Medicine and International Health

Volumn 13, Issue 7, 2008, Pages 870-879

  Keiser, Olivia ^b   Anastos, Kathryn ^b   Schechter, Mauro ^b   Balestre, Eric ^b   Myer, Landon ^b   Boulle, Andrew ^b   Bangsberg, David ^b   Touré, Hapsatou ^b   Braitstein, Paula ^b   Sprinz, Eduardo ^b   Nash, Denis ^b   Hosseinipour, Mina ^b   Dabis, François ^b   May, Margaret ^b   Brinkhof, Martin W G ^b   Egger, Matthias ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Antiretroviral therapy; Asia; Gender identity; Highly active; HIV AIDS; Latin America; Sub Saharan Africa

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ZIDOVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE TREATMENT; GENDER IDENTITY; HUMAN IMMUNODEFICIENCY VIRUS; PUBLIC HEALTH; RESOURCE AVAILABILITY; RESOURCE SCARCITY; TEMPORAL VARIATION; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; ARTICLE; ASIA; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SOUTH AMERICA; SOUTH AND CENTRAL AMERICA; UNDERWEIGHT; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; VIRAL LOAD;

AFRICA; ASIA; EURASIA; LATIN AMERICA; SOUTH AMERICA; SUB-SAHARAN AFRICA;

EID: 44949231219     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02078.x     Document Type: Article

References (40)

1. Anastos K egger@ispm.unibe.ch, Shi Q, French AL et al. (2004) Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 35, 383 392.
2. Beck E, Vitoria JM, Mandalia S et al. (2006) National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 20, 1497 1502.
3. Bekker LG, Myer L, Orrell C et al. (2006) Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. South African Medicne Journal 96, 315 320.
4. Braitstein P, Brinkhof MWG, Dabis F et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817 824.
5. Braitstein P, Boulle A, Nash D et al. (2008) Gender and the use of potent antiretroviral treatment in resource-constrained settings: Findings from a multi-centre collaboration. Journal of Women's Health 17, 47 55.
6. Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887 895.
7. Collumbien M Hawkes S (2000) Missing men's messages: does the reproductive health approach respond to men's sexual health needs? Cult Health Sex 2, 135 150.
8. Dabis F, Balestre E, Braitstein P et al. (2005) Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology 34, 979 986.
9. Djomand G, Roels T, Ellerbrock T et al. (2003) Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 17 (Suppl. 3 S5 S15.
10. Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119 29.
11. Egger M, Boulle A, Schechter M et al. (2005) Antiretroviral therapy in resource-poor settings: scaling up inequalities? International Journal of Epidemiology 34, 509 512.
12. Ehiri JE, Anyanwu CE, Donath E et al. (2005) AIDS-related stigma in sub-Saharan Africa: its contexts and potential intervention strategies. AIDS Public Policy Journal 20, 25 39.
13. Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367, 1335 1342.
14. Fikree FF Pasha O (2004) Role of gender in health disparity: the South Asian context. British Medical Journal 328, 823 826.
15. Gilks CF, Crowley S, Ekpini R et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505 510.
16. Go VF, Sethulakshmi CJ, Bentley ME et al. (2003) When HIV-prevention messages and gender norms clash: the impact of domestic violence on women's HIV risk in slums of Chennai, India. AIDS Behavior 7, 263 272.
17. Greig A Lang J (2000) Men, Masculinities & Development: Broadening Our Work Towards Gender Equality. Gender in Development Monograph Series No. 10. UNDP, Geneva.
18. Ivers LC, Kendrick D Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases 41, 217 224.
19. Lawn SD, Bekker LG, Myer L et al. (2005) Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 19, 2050 2052.
20. Lawn SD, Myer L, Harling G et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clinical Infectious Diseases 43, 770 776.
21. Liechty CA, Solberg P, Were W et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Tropical Medicine and International Health 12, 929 935.
22. May M, Boulle A, Messou E et al. (2008) Mortality of HIV-1 infected patients starting antiretroviral therapy (ART) in sub-Saharan Africa: the IeDEA Prognostic Model 15th Conference on Retroviruses and Opportunistic Infections. Boston. Available at: http://www.retroconference.org/2008 (accessed 17 March 2008).
23. Mekonnen Y, Dukers NH, Sanders E et al. (2003) Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 17, 815 819.
24. Ministry of Health (2004) Health Surveillance Secretariat. National STD/AIDS Programme. Recommendations on Antiretroviral Therapy in HIV-infected Adults and Adolescents. MoH, Brasília.
25. Mocroft A, Kirk O, Barton SE et al. (1999) Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 13, 943 950.
26. Moore RD, Keruly JC Chaisson RE et al. (1998) Anemia and survival in HIV infection. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 19, 29 33.
27. Myer L, Rabkin M, Abrams EJ et al. (2005) Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reproduction and Health Matters 13, 136 146.
28. Nunn AS, Fonseca EM, Bastos FI et al. (2007) Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment. PLoS Medicine 4, e305.
29. Saah AJ, Hoover DR, He Y et al. (1994) Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). Journal of Acquired Immune Deficiency Syndrome 7, 287 295.
30. Sociedad Argentina de Infectiologia (2006) Recomendaciones Sobre Tratamiento Antiretroviral. Actualización SADI. SAI, Buenos Aires.
31. Sullivan PS, Hanson DL, Chu SY et al. (1998) Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 91, 301 308.
32. Tuboi SH, Harrison LH, Sprinz E et al. (2005) Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. Journal of Acquired Immune Deficiency Syndrome 40, 324 328.
33. Tuboi SH, Brinkhof MW, Egger M et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. Journal of Acquired Immune Deficiency Syndrome 45, 52 59.
34. UNAIDS (2006) Report on the Global AIDS Epidemic. Joint United Nations Programme on AIDS, Geneva.
35. Varga CA (2001) The forgotten fifty per cent: a review of sexual and reproductive health research and programs focused on boys and young men in sub-Saharan Africa. African Journal of Reproduction and Health 5, 175 195.
36. World Health Organization (2002) Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach. WHO, Geneva.
37. World Health Organization (2004) Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2003 Revision. WHO, Geneva.
38. World Health Organization (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. WHO, Geneva.
39. World Health Organization, UNAIDS, UNICEF (2007) Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report, April 2007. WHO, Geneva.
40. Zhou J Kumarasamy N (2005) Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine 6, 216 223.